{
  "items": [
    {
      "title": "Stock market sell-off: Why these stocks are in the green amid the pain",
      "description": "The shift to defense is on.",
      "published_utc": "2025-03-11T02:17:12",
      "source": "Yahoo",
      "url": "https://finnhub.io/api/news?id=b4817b2db1f2b2841b7c6941f4f1d8c6378ba55c52a7c3036a715bd6ab90bb31",
      "category": "company",
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related_symbols": [
        "AMGN"
      ],
      "api_source": "finnhub_company",
      "id": 133184559,
      "datetime": 1741630632
    },
    {
      "title": "Amgen: Riding The MariTide Of Monthly Weight Loss",
      "description": "Amgen stock rose 13% as obesity drug MariTide advances. Click here to find out why AMGN stock is a Buy.",
      "published_utc": "2025-03-11T00:46:40",
      "source": "SeekingAlpha",
      "url": "https://finnhub.io/api/news?id=3ec2b5102da8b330ae6a137f5e4d951e50cb5c459820cacda196d8a84ae9be96",
      "category": "company",
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1220400589/image_1220400589.jpg?io=getty-c-w1536",
      "related_symbols": [
        "AMGN"
      ],
      "api_source": "finnhub_company",
      "id": 133127786,
      "datetime": 1741625200
    },
    {
      "title": "Amgen : Update on Patent Litigation Related to Fresenius Denosumab Biosimilar Products",
      "description": "Amgen Update on Patent Litigation Related to Fresenius Denosumab Biosimilar Products We are pleased to have reached resolution of our patent infringement litigation related to...",
      "published_utc": "2025-03-10T23:42:04",
      "source": "Finnhub",
      "url": "https://finnhub.io/api/news?id=4f36151ad6c811da06182b548d3769fb6f8924626ca5419c49780b2c29b9421f",
      "category": "company",
      "image": "",
      "related_symbols": [
        "AMGN"
      ],
      "api_source": "finnhub_company",
      "id": 133125713,
      "datetime": 1741621324
    },
    {
      "title": "AMGN's Eczema Drug Meets Goal in Two Late-Stage Studies",
      "description": "Data from two more late-stage studies show that treatment with Amgen's rocatinlimab improves outcomes in atopic dermatitis indication.",
      "published_utc": "2025-03-10T21:27:00",
      "source": "Yahoo",
      "url": "https://finnhub.io/api/news?id=58ef0150b41d2233a520d9bd77af4d5b028c9786dd73f802323e68c42b56be10",
      "category": "company",
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related_symbols": [
        "AMGN"
      ],
      "api_source": "finnhub_company",
      "id": 133185014,
      "datetime": 1741613220
    },
    {
      "title": "AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS",
      "description": "THOUSAND OAKS, TOKYO - Amgen and Kyowa Kirin Co., Ltd. today announced new results from the ongoing ROCKET Phase 3 clinical trial program evaluating rocatinlimab, an investigational T-cell...",
      "published_utc": "2025-03-10T20:39:17",
      "source": "Finnhub",
      "url": "https://finnhub.io/api/news?id=9f19f7cbf57d1b3d4633eaa509b89e40e9ceba9443c1c02f5b391929fe87e35a",
      "category": "company",
      "image": "",
      "related_symbols": [
        "AMGN"
      ],
      "api_source": "finnhub_company",
      "id": 133122070,
      "datetime": 1741610357
    }
  ],
  "metadata": {
    "cached_at": "2025-09-25T07:16:04.912467+00:00",
    "cache_key": "news_1914596a431a1253af031b9b6e0efc4e",
    "count": 5
  }
}